Association between the commercial characteristics of psychotropic drugs and their off-label use

Medical Care

Volumn 50, Issue 11, 2012, Pages 940-947

  Graziul, Christopher ^a   Gibbons, Robert ^a   Alexander, G Caleb ^b,c,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

mixed effects regression; off label use; psychotropic drugs

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG UTILIZATION; DRUG VOLUME; OFF LABEL DRUG USE; PRIORITY JOURNAL; PRODUCT AGE; PRODUCT PARAMETERS; PROMOTIONAL EXPENDITURE; THERAPEUTIC CLASS AGE;

ADVERTISING AS TOPIC; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DATA COLLECTION; DRUG UTILIZATION; HUMANS; MARKETING; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; TRANQUILIZING AGENTS;

EID: 84867733895     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31826ec272     Document Type: Article

References (29)

1. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Archiv Intern Med. 2006;166:1021-1026.
2. Walton SM, Schumock GT, Lee KV, et al. Prioritizing medications for policy and research initiatives examining off-label prescribing. Phar-macotherapy. 2008;28:1443-1452.
3. Chen H, Deshpande AD, Jiang R, et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf. 2005;14:629-638. (Pubitemid 41358699)
4. Marchetti F, Bua J, Ventura A, et al. The awareness among paediatricians of off-label prescribing in children: a survey of Italian hospitals. Eur J Clin Pharmacol. 2007;63:81-85. (Pubitemid 46025477)
5. Blumer JL. Off-label uses of drugs in children. Pediatrics. 1999; 104:S598-S602.
6. Dai C, Stafford RS, Alexander GC. National trends in Cox-2 inhibitor use since market release: non-selective diffusion of a selectively cost-effective innovation. Archiv Intern Med. 2005;165:171-177.
7. Spiegel A. "How a bone disease grew to fit the prescription." National Public Radio: All Things Considered, 2009. Available at: http://www.npr.org/2009/12/21/121609815/how-a-bone-disease-grew-to-fit-the- prescription. Accessed September 4, 2012.
8. Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment for type 2 diabetes mellitus, 1994-2007. Archiv Intern Med. 2008;168:2088-2094.
9. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61. (Pubitemid 36044404)
10. Zell ER, McCaig LF, Kupronis BA, et al. A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage. Available at: http://www.amstat.org/sections/srms/ Proceedings/papers/2000-143.pdf. Proceedings of the Survey Research Nethods Section, American Statistical Association. Alexandria, VA: American Statistical Association; 2000. Accessed September 4, 2012.
11. Higashi AS, Zhu S, Stafford RS, et al. National trends in outpatient asthma treatment, 1997-2009. J Gen Intern Med. 2011;26:1465-1470.
12. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medicines, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20:177-184.
13. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498-505. (Pubitemid 34441742)
14. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357:673-681. (Pubitemid 47267237)
15. Paczynski RP, Alexander GC, Chinchilli VM, et al. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Int J Risk Saf Med. 2012;24:137-146.
16. Thomson Micromedex DrugDexs Compendium Revision Request- CAG-00391. Centers for Medicare and Medicaid Services, 2008. Available at: http://www.cms.hhs.gov/mcd/ncpc-view-document.asp? id=16. Accessed January 22, 2010.
17. Hedeker D, Gibbons RD. Longitudinal Data Analysis. New York: Wiley; 2006.
18. Chen H, Deshpande AD, Jiang R, et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf. 2005;14:629-638. (Pubitemid 41358699)
19. Chen DT, Wynia MK, Moloney RM, et al. Physician knowledge of the FDA-approved indications of commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf. 2009;18:1-7.
20. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116. (Pubitemid 37430324)
21. Avorn J, Shrank WH. Adverse drug reactions in elderly people: a substantial cause of preventable illness. BMJ. 2008;336:956-957.
22. Zajonc RB. Feeling and thinking: preferences need no inferences. Am Psychol. 1980;35:151-175.
23. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf. 2002;25:1-5. (Pubitemid 34208327)
24. McIntyre J, Conroy S, Avery A, et al. Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child. 2000;83:498-501.
25. Rayburn WF, Turnbull GL. Off-label drug prescribing on a state university obstetric service. J Reprod Med. 1995;40:186-188.
26. Larkin M. Warner-Lambert found guilty of promoting neurontin offlabel. Lancet Neurol. 2004;3:387.
27. Chen H, Deshpande AD, Jiang R, et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf. 2005;14:629-638. (Pubitemid 41358699)
28. Brosgart CL, Mitchell T, Charlebois E, et al. Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:56-62.
29. Alexander GC, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. Med Care. 2008;46:394-402.